BioCentury | Jul 18, 2016
Financial News

Epistem completes placing

...offering: 18.7 million Placement agent: Peel Hunt Investors: Calculus Capital; new investors; existing investors Note: Epistem...
BioCentury | Jun 27, 2016
Financial News

Epistem proposes placing

...prior: 10.6 million Placement agent: Peel Hunt Investors: Calculus Capital; new investors; existing investors Note: Epistem...
BioCentury | Aug 19, 2013
Company News

Biosurfit S.A., Epistem, Qlucore AB, French National Institute of Health and Medical Research (INSERM), Inserm Transfert Initiative diagnostics news

...for the PoC-HCV consortium project to develop point-of-care diagnostics and predictive test for HCV infection. Epistem...
...hand-held Genedrive PCR technology, which has CE Mark approval and provides rapid genotype test results. Epistem...
...Biosurfit, Qlucore, INSERM and INSERM's seed investment arm, Inserm Transfert. Biosurfit S.A. , Lisbon, Portugal Epistem Holdings plc...
BioCentury | May 27, 2013
Company News

Epistem, ScandiDerma A/S deal

...value chemical manufacture through industrial biotechnology" competition. The companies could not be reached for details. Epistem...
...epithelial stem cells. ScandiDerma is developing new dermatological ingredients derived from bioprospecting of arctic species. Epistem Holdings plc...
BioCentury | Dec 17, 2012
Financial News

Epistem completes placing

Epistem Holdings plc (LSE: EHP), Manchester, U.K. Business: Cancer, Gastrointestinal, Gene/Cell therapy Date completed: 12/7/12 Type: Placing Raised: £4.3 million ($6.9 million) Shares: 793,398 Price: 545p Shares after offering: 9.7 million Underwriter: Peel Hunt Investors:...
BioCentury | Aug 13, 2012
Company News

Epistem management update

Epistem Holdings plc (LSE:EHP), Manchester, U.K. Business: Cancer, Gastrointestinal, Gene/Cell therapy Deceased: Co-founder and chief scientific advisor Chris Potten WIR Staff...
BioCentury | Jul 9, 2012
Clinical News

Genedrive regulatory update

...it received CE Mark approval for its Genedrive point-of-care molecular test to diagnose tuberculosis (TB). EpiStem...
...technology is applicable to a range of viral, bacterial, fungal and somatic mutation disease area. EpiStem Holdings plc...
BioCentury | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

...glioblastoma and other brain tumors. CR 3294, an iNOS and matrix metalloproteinase (MMP) co-inhibitor from EpiStem Holdings plc...
BioCentury | Mar 19, 2012
Company News

Epistem, GlaxoSmithKline deal

...The companies partnered to research pulmonary fibrosis biomarkers under a three-year deal. EpiStem will contribute its...
...technology, which measures drug-induced gene expression changes from small tissue samples. Details were not disclosed. EpiStem Holdings plc...
BioCentury | Mar 12, 2012
Company News

Epistem, Xcelris Genomics deal

...EpiStem will be responsible for regulatory approval for the diagnostic to diagnose tuberculosis (TB) infection. EpiStem...
...Program (RNTCP) to identify TB infection at an early stage (see BioCentury, July 4, 2011). EpiStem Holdings plc...
Items per page:
1 - 10 of 31
BioCentury | Jul 18, 2016
Financial News

Epistem completes placing

...offering: 18.7 million Placement agent: Peel Hunt Investors: Calculus Capital; new investors; existing investors Note: Epistem...
BioCentury | Jun 27, 2016
Financial News

Epistem proposes placing

...prior: 10.6 million Placement agent: Peel Hunt Investors: Calculus Capital; new investors; existing investors Note: Epistem...
BioCentury | Aug 19, 2013
Company News

Biosurfit S.A., Epistem, Qlucore AB, French National Institute of Health and Medical Research (INSERM), Inserm Transfert Initiative diagnostics news

...for the PoC-HCV consortium project to develop point-of-care diagnostics and predictive test for HCV infection. Epistem...
...hand-held Genedrive PCR technology, which has CE Mark approval and provides rapid genotype test results. Epistem...
...Biosurfit, Qlucore, INSERM and INSERM's seed investment arm, Inserm Transfert. Biosurfit S.A. , Lisbon, Portugal Epistem Holdings plc...
BioCentury | May 27, 2013
Company News

Epistem, ScandiDerma A/S deal

...value chemical manufacture through industrial biotechnology" competition. The companies could not be reached for details. Epistem...
...epithelial stem cells. ScandiDerma is developing new dermatological ingredients derived from bioprospecting of arctic species. Epistem Holdings plc...
BioCentury | Dec 17, 2012
Financial News

Epistem completes placing

Epistem Holdings plc (LSE: EHP), Manchester, U.K. Business: Cancer, Gastrointestinal, Gene/Cell therapy Date completed: 12/7/12 Type: Placing Raised: £4.3 million ($6.9 million) Shares: 793,398 Price: 545p Shares after offering: 9.7 million Underwriter: Peel Hunt Investors:...
BioCentury | Aug 13, 2012
Company News

Epistem management update

Epistem Holdings plc (LSE:EHP), Manchester, U.K. Business: Cancer, Gastrointestinal, Gene/Cell therapy Deceased: Co-founder and chief scientific advisor Chris Potten WIR Staff...
BioCentury | Jul 9, 2012
Clinical News

Genedrive regulatory update

...it received CE Mark approval for its Genedrive point-of-care molecular test to diagnose tuberculosis (TB). EpiStem...
...technology is applicable to a range of viral, bacterial, fungal and somatic mutation disease area. EpiStem Holdings plc...
BioCentury | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

...glioblastoma and other brain tumors. CR 3294, an iNOS and matrix metalloproteinase (MMP) co-inhibitor from EpiStem Holdings plc...
BioCentury | Mar 19, 2012
Company News

Epistem, GlaxoSmithKline deal

...The companies partnered to research pulmonary fibrosis biomarkers under a three-year deal. EpiStem will contribute its...
...technology, which measures drug-induced gene expression changes from small tissue samples. Details were not disclosed. EpiStem Holdings plc...
BioCentury | Mar 12, 2012
Company News

Epistem, Xcelris Genomics deal

...EpiStem will be responsible for regulatory approval for the diagnostic to diagnose tuberculosis (TB) infection. EpiStem...
...Program (RNTCP) to identify TB infection at an early stage (see BioCentury, July 4, 2011). EpiStem Holdings plc...
Items per page:
1 - 10 of 31